Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Since then, demand for the glucagon-like peptide 1 has skyrocketed ... The phase 3 trials evaluated tirzepatide 10 mg or 15 mg compared with placebo in patients with or without positive airway ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

They received the maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg) for 72 weeks. (No participant had diabetes; Lilly markets tirzepatide as Mounjaro to people with ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide is commercialized for adults ... available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833 ...

Tirzepatide, a dual glucagon-like peptide 1 (GLP-1 ... In both, the participants randomly received either 10 mg or 15 mg of tirzepatide or placebo once weekly for 52 weeks. At baseline, 65% ...